Pharmaceutical Italian pharma major Recordati has set new three-year financial targets for the period 2025-2027, aiming for fiscal year (FY) 2027 revenues of 3.0–3.2 billion euros ($4.1-$4.4 billion) and earnings before interest, tax, depreciation and amortization (EBITDA) of 1.14–1.225 billion euros, driven by a balanced strategy of organic growth, rare disease leadership, and targeted M&A. 29 April 2025